Search results
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
Zacks via Yahoo Finance· 6 days agoBiogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key...
AMPH- A Generic Drugmaker Looking to Expand Via Acquisition, Biosimilars Moves
MoneyShow via Yahoo Finance· 6 days agoAmphastar Pharmaceuticals Inc. (AMPH) is a generic drug company founded in 1996 that went public in 2014. Amphastar focuses on drugs ...
Biodexa gains license for polyposis asset as stock more than doubles
Pharmaceutical Technology via Yahoo Finance· 20 hours agoThe drug won US Food and Drug Administration (FDA) approval in 2021 for the treatment of adult...
Prescription drug shortages hit home in Colorado Springs. Patients, pharmacies, hospitals and...
Colorado Springs Gazette· 2 days agoColorado resident Tara Roesener wasn’t aware of a widespread prescription drug shortage until about...
Walmart to shutter health centers, virtual care service in latest failed push into health care
CNBC· 2 hours agoWalmart will close 51 clinic locations across Arkansas, Florida, Georgia, Illinois and Texas, plans...
BioMarin stock falls 9% in wake of Q1 report, pipeline updates
Seeking Alpha· 5 days agoBioMarin (BMRN) stock fell 9% Thursday, the day after the company released its Q1 earnings report...
4 Large Drug Stocks to Hold on to Amid Industry Challenges
Zacks via Yahoo Finance· 6 days agoDrug and biotech companies are likely to see significant innovation. In the Large-Cap...
White House Plan To Curb Drug Shortages Doesn’t Address Generics’ Quality
Forbes· 6 days agoDrug shortages are at an all-time high. The White House rolled out a plan earlier this month...
Is Eli Lilly Stock A Buy After Weight-Loss Drug Succeeds In Sleep Apnea Patients?
Investor's Business Daily· 5 days agoThe company also calls for adjusted earnings of $12.20 to $12.70 per share. Both measures...to bring...
Is Bristol Myers Squibb Stock a Millionaire Maker?
Motley Fool via Yahoo Finance· 5 days agoAnd in Revlimid's case, it is already facing competition from generics. Revenue fell by 3% last year to just over $45 billion, the second straight...t...